Skip to content
Clinical Trials – home

Adenocarcinoma Treatment

1 / 1 trials open to patients4 countries

In short

Adenocarcinoma is a type of cancer that begins in the gland cells that line organs throughout the body. This form of cancer can affect the lungs, breasts, colon, pancreas, prostate, stomach, and other organs where glands produce fluids like mucus and digestive juices. Treatment depends on where the cancer is located, how far it has spread, and the overall health of the patient. Both established medical treatments and innovative therapies tested in clinical trials offer hope to those facing this diagnosis.

Key points

  • Adenocarcinoma treatment must be personalized based on where the cancer is located, how far it has spread, and each patient's unique health situation and preferences.
  • Early detection significantly improves treatment outcomes—many adenocarcinomas can be successfully removed through surgery when caught before spreading.
  • Modern treatment combines multiple approaches including surgery, chemotherapy, radiation, targeted therapy, and immunotherapy, often used in combination for best results.
  • Biomarker testing can identify specific genetic changes in tumors that make them vulnerable to targeted therapies, potentially offering more effective treatment with fewer side effects.
  • Clinical trials are testing innovative approaches including new immunotherapy methods, combinations of existing drugs, and precision medicine strategies tailored to individual tumor characteristics.
  • Managing side effects and maintaining quality of life are integral parts of adenocarcinoma care—healthcare teams offer extensive support for physical symptoms, nutrition, pain control, and emotional well-being.
  • Treatment decisions should always involve open communication with your healthcare team, who can explain options, answer questions, and help you make choices aligned with your goals and values.

Understanding Treatment Goals and Approaches

When someone receives an adenocarcinoma diagnosis, the main goal of treatment is to control or eliminate the cancer, reduce symptoms, and help the patient maintain the best possible quality of life. Treatment strategies are carefully tailored based on several factors: the specific organ where the cancer started, how advanced the disease is when discovered, and the patient's individual health profile and preferences.

The approach to treating adenocarcinoma varies considerably depending on its location in the body. For example, adenocarcinoma in the lungs may require different strategies than adenocarcinoma in the colon or breast. In early stages, when the cancer is confined to one area, treatment may focus on removing the tumor completely through surgery. In more advanced stages, when cancer has spread to other tissues or organs, treatment aims to slow the disease's progression, manage pain and other symptoms, and extend survival while maintaining dignity and comfort.

Medical societies and expert panels have developed standard treatment guidelines based on years of research and clinical experience. These guidelines help doctors choose the most effective treatments that have been proven to work. At the same time, researchers around the world are constantly testing new therapies through clinical trials—carefully controlled studies that investigate whether new treatments are safe and effective. These trials represent the cutting edge of cancer care and may offer additional options for patients whose cancer does not respond well to standard treatments.

Standard Medical Treatments for Adenocarcinoma

The foundation of adenocarcinoma treatment typically involves one or more of three main approaches: surgery, chemotherapy (medication that kills cancer cells), and radiation therapy (high-energy beams that destroy cancer cells). The choice among these options depends heavily on where the cancer is located and how far it has spread.

Surgical Treatment

When adenocarcinoma is detected early and has not spread beyond its original location, surgery often provides the best chance for a cure. The surgeon removes the tumor along with a margin of healthy tissue surrounding it to ensure all cancer cells are eliminated. The specific surgical procedure varies by organ. For lung adenocarcinoma, this might involve removing part or all of a lung. For colon adenocarcinoma, surgeons remove the affected section of the intestine. In breast adenocarcinoma, surgery may involve removing just the tumor (lumpectomy) or the entire breast (mastectomy).

After surgery, many patients receive additional treatment to reduce the risk of cancer returning. This is called adjuvant therapy and often includes chemotherapy or radiation. The duration of post-surgical treatment varies but can last several weeks to months.

Chemotherapy

Chemotherapy uses powerful medications to kill rapidly dividing cells throughout the body. These drugs travel through the bloodstream, which makes them useful for treating cancer that has spread beyond its original location or to reduce the risk of cancer returning after surgery. Different chemotherapy drugs work in different ways—some damage the DNA inside cancer cells, while others interfere with cell division.

The challenge with chemotherapy is that it affects not only cancer cells but also healthy cells that naturally divide quickly, such as those in hair follicles, the digestive system lining, and bone marrow. This is why chemotherapy commonly causes side effects like hair loss, nausea and vomiting, diarrhea, fatigue, and increased risk of infection due to lower white blood cell counts. Healthcare teams carefully monitor patients during chemotherapy and can provide medications to help manage these side effects.

Chemotherapy is typically given in cycles—periods of treatment followed by rest periods to allow the body to recover. The complete treatment course may last several months. The specific drugs used depend on the type and stage of adenocarcinoma. For example, colorectal adenocarcinoma might be treated with drugs like fluorouracil or oxaliplatin, while lung adenocarcinoma might require different combinations.

Radiation Therapy

Radiation therapy uses high-energy beams similar to X-rays to kill cancer cells or prevent them from growing. Unlike chemotherapy, radiation is a local treatment—it affects only the specific area being treated. Radiation may be used before surgery to shrink tumors, after surgery to eliminate any remaining cancer cells, or as the main treatment when surgery is not possible.

Modern radiation therapy is highly precise, using advanced imaging to target cancer while minimizing damage to surrounding healthy tissue. Treatments are usually given five days a week for several weeks. Side effects depend on the body area being treated but commonly include skin irritation, fatigue, and temporary inflammation of tissues in the radiation field. Most side effects improve after treatment ends.

Targeted Therapy

For some types of adenocarcinoma, doctors can use targeted therapies—drugs designed to attack specific molecules that help cancer cells grow and survive. These treatments are different from traditional chemotherapy because they focus on particular abnormalities within cancer cells rather than simply killing all rapidly dividing cells. This often results in fewer side effects.

Targeted therapy works best when specific genetic changes or protein abnormalities are identified in the cancer through specialized testing called biomarker testing or molecular profiling. For example, some lung adenocarcinomas have mutations in genes called EGFR or ALK, and specific medications can target these abnormalities. Before recommending targeted therapy, doctors typically perform tests on a sample of the tumor to determine if these specific targets are present.

Immunotherapy

Immunotherapy is a newer approach that helps the body's own immune system recognize and attack cancer cells. Cancer cells sometimes hide from the immune system by producing proteins that act like "off switches." Immunotherapy drugs can block these proteins, allowing immune cells to identify and destroy the cancer. Drugs called checkpoint inhibitors are one type of immunotherapy now used for certain adenocarcinomas, particularly lung and colorectal cancers in specific situations.

Immunotherapy can cause different side effects than chemotherapy. Because it activates the immune system, it can sometimes cause the immune system to attack healthy tissues, leading to inflammation in organs like the lungs, intestines, liver, or hormone-producing glands. Healthcare teams watch for these effects and can treat them with medications that calm the immune response if needed.

Emerging Treatments in Clinical Trials

Beyond standard treatments, researchers are continually developing and testing new therapies for adenocarcinoma through clinical trials. These studies occur in phases, each designed to answer specific questions about a new treatment.

Understanding Clinical Trial Phases

Phase I trials are the first stage of testing in humans. They primarily assess whether a new treatment is safe, determine the appropriate dose, and identify side effects. These trials usually involve a small number of patients, often those whose cancer has not responded to standard treatments. Phase I studies help researchers understand how the human body processes the new drug and what dose can be tolerated.

Phase II trials test whether the treatment actually works against cancer. These studies enroll more patients and focus on measuring how well the treatment shrinks tumors or slows cancer growth. Researchers also continue monitoring safety and side effects during this phase. If a treatment shows promise in Phase II, it moves forward to larger studies.

Phase III trials compare the new treatment directly against the current standard treatment. These are large studies that may involve hundreds or thousands of patients at medical centers around the world. The goal is to determine whether the new treatment is better than, worse than, or equivalent to existing options. Results from successful Phase III trials often lead to approval of new treatments by regulatory agencies like the U.S. Food and Drug Administration.

New Immunotherapy Approaches

While some immunotherapy drugs are now standard treatment, researchers are testing additional ways to harness the immune system against adenocarcinoma. One approach involves cancer vaccines—not vaccines to prevent cancer, but treatments designed to teach the immune system to recognize specific proteins on cancer cells. These experimental vaccines are being studied for various types of adenocarcinoma in clinical trials across the United States and internationally.

Another innovative approach is CAR-T cell therapy, which involves removing a patient's own immune cells, genetically modifying them in a laboratory to better recognize cancer cells, and then infusing them back into the patient. While this approach has shown remarkable success in certain blood cancers, researchers are now investigating whether similar strategies can work against solid tumors like adenocarcinomas. These trials are typically available at specialized cancer centers.

Targeted Therapy Innovations

Scientists continue discovering new molecular targets in adenocarcinoma cells. Clinical trials are testing drugs that block specific growth signals, prevent cancer cells from developing their own blood supply, or interfere with DNA repair mechanisms that cancer cells use to survive. Many of these experimental drugs focus on targeting multiple pathways simultaneously, which may make it harder for cancer to develop resistance.

For lung adenocarcinoma specifically, researchers are testing new drugs for patients whose tumors have less common genetic mutations. While medications already exist for common mutations like EGFR and ALK, trials are evaluating treatments for mutations in genes like KRAS, BRAF, MET, and RET. Some of these drugs have shown encouraging results in early studies, with patients experiencing tumor shrinkage and improved symptoms.

Combination Therapies

Many clinical trials now test combinations of different treatments used together. For example, researchers are studying whether combining immunotherapy with targeted therapy might work better than either treatment alone. Other trials combine immunotherapy with chemotherapy or radiation therapy. The reasoning is that different treatments may attack cancer through different mechanisms, potentially leading to better results. However, combinations must be tested carefully to ensure the side effects are manageable.

Precision Medicine Approaches

Precision medicine involves selecting treatments based on the unique genetic and molecular characteristics of each patient's cancer rather than only considering where in the body the cancer started. Advanced testing techniques can now identify dozens of different genetic changes within tumors. Clinical trials are investigating whether matching patients to treatments based on these specific changes leads to better outcomes, regardless of whether the adenocarcinoma is in the lung, colon, or another organ.

Accessing Clinical Trials

Clinical trials for adenocarcinoma are conducted at cancer centers throughout the United States, Europe, and other regions worldwide. Major academic medical centers often have the most extensive trial portfolios. Patients interested in clinical trials can discuss options with their oncologist, who may refer them to centers conducting relevant studies. Online databases also allow patients to search for trials based on their specific type of adenocarcinoma and other factors.

Most Common Treatment Methods

  • Surgery
    • Removal of tumor and surrounding tissue in early-stage disease
    • Different procedures depending on organ affected (lumpectomy, mastectomy, lung resection, colon resection)
    • Often combined with adjuvant therapy after surgery to prevent recurrence
  • Chemotherapy
    • Systemic drugs that kill rapidly dividing cells throughout the body
    • Given in cycles over several months
    • Specific drug combinations vary by adenocarcinoma type and stage
    • Common side effects include hair loss, nausea, fatigue, and lowered immunity
  • Radiation Therapy
    • High-energy beams targeted at specific tumor locations
    • Used before or after surgery, or as main treatment when surgery not possible
    • Typically administered five days per week for several weeks
    • Side effects depend on treatment area but often include skin irritation and fatigue
  • Targeted Therapy
    • Drugs designed to attack specific molecular abnormalities in cancer cells
    • Requires biomarker testing to identify appropriate targets
    • Examples include EGFR and ALK inhibitors for lung adenocarcinoma
    • Generally fewer side effects than traditional chemotherapy
  • Immunotherapy
    • Checkpoint inhibitors that help immune system recognize cancer
    • Used for certain lung and colorectal adenocarcinomas
    • Can cause immune-related side effects affecting various organs
    • Newer approaches in clinical trials include cancer vaccines and CAR-T cell therapy

Managing Treatment Side Effects and Quality of Life

While treating adenocarcinoma, managing side effects and maintaining quality of life are essential parts of care. Modern cancer treatment includes supportive therapies that help patients feel better and function more normally during and after treatment.

Side effects vary depending on the type of treatment. Chemotherapy commonly causes nausea, which can now be well-controlled with anti-nausea medications. Fatigue is another frequent issue with many cancer treatments. Patients are encouraged to balance rest with gentle physical activity, as moderate exercise actually helps combat treatment-related tiredness. Nutritional support is important when appetite decreases or swallowing becomes difficult—dietitians can recommend strategies to maintain adequate nutrition even when eating is challenging.

Pain management is a critical component of adenocarcinoma care, especially in advanced stages. Pain may come from the tumor itself, from treatments, or from procedures. Healthcare teams have many effective options for pain control, from over-the-counter medications for mild discomfort to prescription opioids for severe pain. The goal is to keep pain at manageable levels so patients can continue daily activities and maintain their quality of life.

Emotional and mental health support is equally important. A cancer diagnosis naturally brings feelings of fear, anxiety, sadness, or anger. These reactions are normal and valid. Support groups—whether in-person or online—allow patients to connect with others facing similar challenges. Many find comfort in sharing experiences and learning how others cope. Professional counseling or therapy can also help patients and families navigate the emotional complexities of living with cancer.

Did you know?

  1. Adenocarcinoma is the most common form of lung cancer in people who have never smoked, representing about 40% of all lung cancers overall.
  2. Nearly all prostate cancers (99%) are adenocarcinomas, making it by far the predominant cell type in this organ, while 85% of pancreatic cancers are also adenocarcinomas.
  3. In the last two decades, adenocarcinoma has replaced squamous cell cancer as the most prevalent type of non-small cell lung cancer, partly due to changes in cigarette composition and smoking patterns.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Adenocarcinoma

Recruiting trials first

See all 1 trials →
Quick filters

1 clinical trial in this condition

Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tub-040
  • Sponsor:Gilead Sciences Inc.
See all 1 trials →filters applied: condition = Adenocarcinoma

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).